---
pmid: '26175413'
title: CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence
  and Demonstrates Efficacy in Myeloproliferative Neoplasms.
authors:
- Meyer SC
- Keller MD
- Chiu S
- Koppikar P
- Guryanova OA
- Rapaport F
- Xu K
- Manova K
- Pankov D
- O'Reilly RJ
- Kleppe M
- McKenney AS
- Shih AH
- Shank K
- Ahn J
- Papalexi E
- Spitzer B
- Socci N
- Viale A
- Mandon E
- Ebel N
- Andraos R
- Rubert J
- Dammassa E
- Romanet V
- Dölemeyer A
- Zender M
- Heinlein M
- Rampal R
- Weinberg RS
- Hoffman R
- Sellers WR
- Hofmann F
- Murakami M
- Baffert F
- Gaul C
- Radimerski T
- Levine RL
journal: Cancer Cell
year: '2015'
pmcid: PMC4503933
doi: 10.1016/j.ccell.2015.06.006
---

# CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
**Authors:** Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL
**Journal:** Cancer Cell (2015)
**DOI:** [10.1016/j.ccell.2015.06.006](https://doi.org/10.1016/j.ccell.2015.06.006)
**PMC:** [PMC4503933](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503933/)

## Abstract

1. Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and 
Demonstrates Efficacy in Myeloproliferative Neoplasms.

Meyer SC(1), Keller MD(1), Chiu S(1), Koppikar P(1), Guryanova OA(1), Rapaport 
F(1), Xu K(2), Manova K(2), Pankov D(3), O'Reilly RJ(3), Kleppe M(1), McKenney 
AS(1), Shih AH(1), Shank K(1), Ahn J(1), Papalexi E(1), Spitzer B(1), Socci 
N(4), Viale A(4), Mandon E(5), Ebel N(5), Andraos R(5), Rubert J(5), Dammassa 
E(5), Romanet V(5), Dölemeyer A(5), Zender M(5), Heinlein M(5), Rampal R(6), 
Weinberg RS(7), Hoffman R(8), Sellers WR(9), Hofmann F(5), Murakami M(5), 
Baffert F(5), Gaul C(5), Radimerski T(10), Levine RL(11).

Author information:
(1)Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer 
Center, New York, NY 10065, USA.
(2)Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 
10065, USA.
(3)Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, 
NY 10065, USA.
(4)Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New 
York, NY 10065, USA.
(5)Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
(6)Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer 
Center, New York, NY 10065, USA; Leukemia Service, Department of Medicine, 
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
(7)New York Blood Center, New York, NY 10065, USA.
(8)Department of Medicine, Mount Sinai Hospital, New York, NY 10029, USA.
(9)Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
(10)Novartis Institutes for Biomedical Research, Basel 4056, Switzerland. 
Electronic address: thomas.radimerski@novartis.com.
(11)Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer 
Center, New York, NY 10065, USA; Leukemia Service, Department of Medicine, 
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic 
address: leviner@mskcc.org.

Comment in
    Cancer Cell. 2015 Jul 13;28(1):1-2. doi: 10.1016/j.ccell.2015.06.010.

Although clinically tested JAK inhibitors reduce splenomegaly and systemic 
symptoms, molecular responses are not observed in most myeloproliferative 
neoplasm (MPN) patients. We previously demonstrated that MPN cells become 
persistent to type I JAK inhibitors that bind the active conformation of JAK2. 
We investigated whether CHZ868, a type II JAK inhibitor, would demonstrate 
activity in JAK inhibitor persistent cells, murine MPN models, and MPN patient 
samples. JAK2 and MPL mutant cell lines were sensitive to CHZ868, including type 
I JAK inhibitor persistent cells. CHZ868 showed significant activity in murine 
MPN models and induced reductions in mutant allele burden not observed with type 
I JAK inhibitors. These data demonstrate that type II JAK inhibition is a viable 
therapeutic approach for MPN patients.

Copyright © 2015 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccell.2015.06.006
PMCID: PMC4503933
PMID: 26175413 [Indexed for MEDLINE]

## Full Text

Although clinically tested JAK inhibitors reduce splenomegaly and systemic symptoms, molecular responses are not observed in most myeloproliferative neoplasms (MPN) patients. We previously demonstrated that MPN cells become persistent to type I JAK inhibitors that bind the active conformation of JAK2. We investigated if CHZ868, a type II JAK inhibitor, would demonstrate activity in JAK inhibitor persistent cells, murine MPN models, and MPN patient samples. JAK2- and MPL-mutant cell lines were sensitive to CHZ868, including type I JAK inhibitor persistent cells. CHZ868 showed significant activity in murine MPN models and induced reductions in mutant allele burden not observed with type I JAK inhibitors. These data demonstrate that type II JAK inhibition is a viable therapeutic approach for MPN patients.
